stockrowAlcon
ALC Healthcare Medical Instruments & Supplies
Alcon’s revenue for fiscal 2025 (year ended December 2025) was $10.4 billion, up 4.94% from fiscal 2024.
- Revenue
- +8.74%
- EPS
- −100.0%
- Free cash flow
- −0.54%
- Total debt
- −0.55%
Quarter to June 2026, against a year earlier
Follow ALC
Alert me
Alcon (ALC) Total debt
Alcon's total debt at the end of fiscal 2025 was $4.7B, unchanged from fiscal 2024. At the end of the quarter to 30 June 2026 it was $4.7B. Over the past ten years it has ranged from $136.8M (fiscal 2018) to $4.7B (fiscal 2023); the current reading is higher than 90% of that period. Alcon ranks 5th of 50 Medical Instruments & Supplies companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $4.7B | 2.02% |
| FY2024 | $4.6B | (2.03%) |
| FY2023 | $4.7B | 1.96% |
| FY2022 | $4.6B | 13.92% |
| FY2021 | $4.1B | (0.92%) |
| FY2020 | $4.1B | 18.37% |
| FY2019 | $3.5B | 2,443.20% |
| FY2018 | $136.8M | (7.54%) |
| FY2017 | $148.0M | (40.35%) |
| FY2016 | $248.0M | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Jun 2026 | $4.7B | (0.32%) |
| Mar 2026 | $4.7B | (0.06%) |
| Dec 2025 | $4.7B | 0.08% |
| Sep 2025 | $4.7B | (0.25%) |
| 26 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| BDX Becton, Dickinson and Company compare | $13.5B |
| MDLN Medline Inc. compare | $12.6B |
| BAX Baxter International Inc. compare | $8.6B |
| ALC Alcon | $4.7B |
| COO The Cooper Companies, Inc. compare | $2.5B |
| SOLV Solventum Corporation compare | $507.0M |
| RMD ResMed Inc. compare | $249.6M |
| WST West Pharmaceutical Services, Inc. compare | $202.9M |
| ALGN Align Technology, Inc. compare | $127.0M |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on ALC
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Beneish M-score
- The full statement